ΠΠΎΠΌΠ°ΡΠ½Ρ ΡΡΠΎΡΡΠ½ΠΊΠ°EKSO β’ NASDAQ
add
Ekso Bionics Holdings Inc
8,26Β $
ΠΠΎ Π²ΡΠ΄ΠΊΡΠΈΡΡΡ ΡΠΈΠ½ΠΊΡ:(0,00%)0,00
8,26Β $
ΠΠ°ΠΊΡΠΈΡΠΎ: 28 ΡΡΡ., 06:02:46 GMT-5 · USD · NASDAQ · ΠΠ°ΡΡΠ΅ΡΠ΅ΠΆΠ΅Π½Π½Ρ
ΠΠΊΡΡΡΠΠ°ΡΠ΅ΡΡΡΡΠΎΠ²Π°Π½ΠΎ Π² ΡΠ°ΠΊΠΎΠΌΡ ΡΠ΅Π³ΡΠΎΠ½Ρ: Π‘Π¨ΠΠΠΎΠ»ΠΎΠ²Π½ΠΈΠΉ ΠΎΡΡΡ: Π‘Π¨Π
ΠΠ°ΠΊΡΠΈΡΡΡ ΠΏΠΎΠΏΠ΅Ρ. Π΄Π½Ρ
7,92Β $
ΠΡΠ°ΠΏΠ°Π·ΠΎΠ½ ΡΡΠ½ Π·Π° Π΄Π΅Π½Ρ
7,55Β $ - 8,39Β $
ΠΡΠ°ΠΏΠ°Π·ΠΎΠ½ ΡΡΠ½ Π·Π° ΡΡΠΊ
2,75Β $ - 12,70Β $
Π ΠΈΠ½ΠΊΠΎΠ²Π° ΠΊΠ°ΠΏΡΡΠ°Π»ΡΠ·Π°ΡΡΡ
28,02Β ΠΌΠ»Π½ USD
Π‘Π΅Ρ. ΠΎΠ±ΡΡΠ³
4,16Β ΠΌΠ»Π½
ΠΠΎΠ΅ΡΡΡΡΡΠ½Ρ ΡΡΠ½Π°/ΠΏΡΠΈΠ±ΡΡΠΎΠΊ
-
ΠΠΈΠ²ΡΠ΄Π΅Π½Π΄Π½ΠΈΠΉ ΠΏΡΠΈΠ±ΡΡΠΎΠΊ
-
ΠΡΠ½ΠΎΠ²Π½Π° Π±ΡΡΠΆΠ°
NASDAQ
Π£ Π½ΠΎΠ²ΠΈΠ½Π°Ρ
Π€ΡΠ½Π°Π½ΡΠΎΠ²Ρ Π΄Π°Π½Ρ
ΠΠ²ΡΡ ΠΏΡΠΎ ΡΡΠ½Π°Π½ΡΠΎΠ²Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΈ
ΠΠΎΡ
ΡΠ΄
Π§ΠΈΡΡΠΈΠΉ Π΄ΠΎΡ
ΡΠ΄
| (USD) | Π²Π΅Ρ. 2025β―Ρ.info | ΠΠΌΡΠ½Π° Π·Π° ΡΡΠΊ |
|---|---|---|
ΠΠΎΡ
ΡΠ΄ | 4,23Β ΠΌΠ»Π½ | 2,37% |
ΠΠΏΠ΅ΡΠ°ΡΡΠΉΠ½Ρ Π²ΠΈΡΡΠ°ΡΠΈ | 3,95Β ΠΌΠ»Π½ | -18,50% |
Π§ΠΈΡΡΠΈΠΉ Π΄ΠΎΡ
ΡΠ΄ | -1,42Β ΠΌΠ»Π½ | 31,42% |
ΠΠ°ΡΠΆΠ° ΡΠΈΡΡΠΎΠ³ΠΎ ΠΏΡΠΈΠ±ΡΡΠΊΡ | -33,62 | 33,00% |
ΠΡΠΈΠ±ΡΡΠΎΠΊ Π½Π° Π°ΠΊΡΡΡ | β | β |
EBITDA | -1,04Β ΠΌΠ»Π½ | 53,63% |
ΠΡΠ΅ΠΊΡΠΈΠ²Π½Π° ΡΡΠ°Π²ΠΊΠ° ΠΏΠΎΠ΄Π°ΡΠΊΡ | β | β |
ΠΡΡ
Π³Π°Π»ΡΠ΅ΡΡΡΠΊΠΈΠΉ Π±Π°Π»Π°Π½Ρ
ΠΠ°Π³Π°Π»ΡΠ½Π° Π²Π°ΡΡΡΡΡΡ Π°ΠΊΡΠΈΠ²ΡΠ²
ΠΠ°Π³Π°Π»ΡΠ½Π° ΡΡΠΌΠ° Π·ΠΎΠ±ΠΎΠ²βΡΠ·Π°Π½Ρ
| (USD) | Π²Π΅Ρ. 2025β―Ρ.info | ΠΠΌΡΠ½Π° Π·Π° ΡΡΠΊ |
|---|---|---|
ΠΠΎΡΡΠ²ΠΊΠΎΠ²Ρ ΠΉ ΠΊΠΎΡΠΎΡΠΊΠΎΡΡΡΠΎΠΊΠΎΠ²Ρ Π²ΠΊΠ»Π°Π΄ΠΈ | 2,72Β ΠΌΠ»Π½ | -67,17% |
ΠΠ°Π³Π°Π»ΡΠ½Π° Π²Π°ΡΡΡΡΡΡ Π°ΠΊΡΠΈΠ²ΡΠ² | 21,66Β ΠΌΠ»Π½ | -25,84% |
ΠΠ°Π³Π°Π»ΡΠ½Π° ΡΡΠΌΠ° Π·ΠΎΠ±ΠΎΠ²βΡΠ·Π°Π½Ρ | 11,98Β ΠΌΠ»Π½ | -16,44% |
ΠΠ°Π³. ΡΡΠΌΠ° Π²Π»Π°ΡΠ½. ΠΊΠ°ΠΏΡΡΠ°Π»Ρ | 9,68Β ΠΌΠ»Π½ | β |
Π¦ΠΈΡΠΊΡΠ»ΡΡΡΡ Π°ΠΊΡΡΡ | 2,62Β ΠΌΠ»Π½ | β |
P/B ΠΊΠΎΠ΅ΡΡΡΡΡΠ½Ρ | 2,15 | β |
Π Π΅Π½ΡΠ°Π±Π΅Π»ΡΠ½ΡΡΡΡ Π°ΠΊΡΠΈΠ²ΡΠ² | -15,64% | β |
Π Π΅Π½ΡΠ°Π±Π΅Π»ΡΠ½ΡΡΡΡ ΠΊΠ°ΠΏΡΡΠ°Π»Ρ | -22,65% | β |
ΠΡΠΎΡΠΎΠ²ΠΈΠΉ ΠΏΠΎΡΡΠΊ
Π§ΠΈΡΡΠ° Π·ΠΌΡΠ½Π° Π·Π°Π»ΠΈΡΠΊΡ Π³ΠΎΡΡΠ²ΠΊΠΈ
| (USD) | Π²Π΅Ρ. 2025β―Ρ.info | ΠΠΌΡΠ½Π° Π·Π° ΡΡΠΊ |
|---|---|---|
Π§ΠΈΡΡΠΈΠΉ Π΄ΠΎΡ
ΡΠ΄ | -1,42Β ΠΌΠ»Π½ | 31,42% |
ΠΠΎΡΡΠ²ΠΊΠ° Π²ΡΠ΄ ΠΎΠΏΠ΅ΡΠ°ΡΡΠΉ | -2,06Β ΠΌΠ»Π½ | 9,49% |
ΠΠΎΡΡΠ²ΠΊΠ° Π²ΡΠ΄ ΡΠ½Π²Π΅ΡΡΠΈΡΡΠΉ | -12,00Β ΡΠΈΡ. | -50,00% |
ΠΠΎΡΡΠ²ΠΊΠ° Π²ΡΠ΄ ΡΡΠ½Π°Π½ΡΡΠ²Π°Π½Π½Ρ | -437,00Β ΡΠΈΡ. | -109,32% |
Π§ΠΈΡΡΠ° Π·ΠΌΡΠ½Π° Π·Π°Π»ΠΈΡΠΊΡ Π³ΠΎΡΡΠ²ΠΊΠΈ | -2,52Β ΠΌΠ»Π½ | -204,69% |
ΠΡΠ»ΡΠ½ΠΈΠΉ Π³ΡΠΎΡΠΎΠ²ΠΈΠΉ ΠΏΠΎΡΡΠΊ | -1,37Β ΠΌΠ»Π½ | -22,71% |
ΠΠ½ΡΠΎΡΠΌΠ°ΡΡΡ
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
ΠΠ΅Π½Π΅ΡΠ°Π»ΡΠ½ΠΈΠΉ Π΄ΠΈΡΠ΅ΠΊΡΠΎΡ
ΠΠ°ΡΠ° Π·Π°ΡΠ½ΡΠ²Π°Π½Π½Ρ
2005
ΠΠΎΠ»ΠΎΠ²Π½ΠΈΠΉ ΠΎΡΡΡ
ΠΠ΅Π±-ΡΠ°ΠΉΡ
ΠΡΠ»ΡΠΊΡΡΡΡ ΠΏΡΠ°ΡΡΠ²Π½ΠΈΠΊΡΠ²
61